Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2016
This article has no abstract
Epistemonikos ID: 978242e9a6df472bc659cf8d5bce6f25efc743ea
First added on: Apr 29, 2026